ATE285227T1 - Pharmazeutische granulate mit intragranulärem sprengmittel - Google Patents

Pharmazeutische granulate mit intragranulärem sprengmittel

Info

Publication number
ATE285227T1
ATE285227T1 AT97200653T AT97200653T ATE285227T1 AT E285227 T1 ATE285227 T1 AT E285227T1 AT 97200653 T AT97200653 T AT 97200653T AT 97200653 T AT97200653 T AT 97200653T AT E285227 T1 ATE285227 T1 AT E285227T1
Authority
AT
Austria
Prior art keywords
intragranular
explosives
pharmaceutical granules
granules
pharmaceutical
Prior art date
Application number
AT97200653T
Other languages
English (en)
Inventor
Luis Carvajal Martin
Juan Dedios Romero
Original Assignee
Beecham Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Lab Sa filed Critical Beecham Lab Sa
Application granted granted Critical
Publication of ATE285227T1 publication Critical patent/ATE285227T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97200653T 1991-05-08 1992-05-02 Pharmazeutische granulate mit intragranulärem sprengmittel ATE285227T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919109862A GB9109862D0 (en) 1991-05-08 1991-05-08 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ATE285227T1 true ATE285227T1 (de) 2005-01-15

Family

ID=10694582

Family Applications (3)

Application Number Title Priority Date Filing Date
AT97200652T ATE252900T1 (de) 1991-05-08 1992-05-02 Pharmazeutische granulate mit intragranularem sprengmittel
AT97200653T ATE285227T1 (de) 1991-05-08 1992-05-02 Pharmazeutische granulate mit intragranulärem sprengmittel
AT92909160T ATE203400T1 (de) 1991-05-08 1992-05-02 Pharmazeutische formulierungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97200652T ATE252900T1 (de) 1991-05-08 1992-05-02 Pharmazeutische granulate mit intragranularem sprengmittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92909160T ATE203400T1 (de) 1991-05-08 1992-05-02 Pharmazeutische formulierungen

Country Status (33)

Country Link
US (3) US6110497A (de)
EP (3) EP0585252B1 (de)
JP (1) JPH06507396A (de)
KR (1) KR100228450B1 (de)
CN (2) CN1056277C (de)
AP (1) AP328A (de)
AT (3) ATE252900T1 (de)
AU (1) AU659836B2 (de)
BR (1) BR9205948A (de)
CA (1) CA2102630C (de)
CZ (1) CZ291795B6 (de)
DE (3) DE69233239T2 (de)
DK (1) DK0585252T3 (de)
ES (3) ES2161690T3 (de)
FI (1) FI110354B (de)
GB (1) GB9109862D0 (de)
GR (1) GR3036937T3 (de)
HU (1) HU219348B (de)
IE (1) IE921472A1 (de)
IL (1) IL101795A (de)
MA (1) MA22522A1 (de)
MX (1) MX9202118A (de)
MY (1) MY111879A (de)
NO (1) NO312224B1 (de)
NZ (1) NZ242625A (de)
PT (1) PT100458B (de)
SA (1) SA92130069B1 (de)
SG (1) SG55163A1 (de)
SK (1) SK282333B6 (de)
TW (1) TW240172B (de)
WO (1) WO1992019227A2 (de)
YU (1) YU49069B (de)
ZA (1) ZA923272B (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
WO1997006798A2 (en) * 1995-08-12 1997-02-27 Smithkline Beecham Plc Pharmaceutical formulations
DE69617036T2 (de) 1995-09-07 2002-07-11 Smithkline Beecham Corp., King Of Prussia Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung
WO1997031639A1 (fr) * 1996-02-29 1997-09-04 Fujisawa Pharmaceutical Co., Ltd. COMPRIMES CONTENANT UN ANTIBIOTIQUE AU β-LACTAME ET PROCEDE POUR LEUR PRODUCTION
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
US6893664B1 (en) 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
WO1998034598A2 (en) * 1997-02-07 1998-08-13 Gist-Brocades B.V. Homogeneous granulated formulations for dose sipping technology
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
AP1253A (en) * 1997-02-14 2004-03-17 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate.
TR200000529T2 (tr) * 1997-08-29 2000-08-21 Dsm N.V. İçinde eksipiyan olmayan granüller
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
AU1232500A (en) * 1998-10-30 2000-05-22 Fuisz International Ltd. Improved amoxycillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
CN1209099C (zh) 1999-04-01 2005-07-06 Dsm公司 结晶化附聚物
EA004310B1 (ru) * 1999-04-13 2004-02-26 Бичам Фармасьютикалз (Пте) Лимитед Новый способ лечения
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US20020006433A1 (en) * 1999-04-29 2002-01-17 Nigel P. Davidson Pharmaceutical formulations
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
CA2424462C (en) * 2000-10-20 2010-03-30 Biochemie Gesellschaft M.B.H. Clavulanic acid pharmaceutical compositions
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
AT413983B (de) * 2001-04-12 2006-08-15 Sandoz Ag K-clavulanat in der form eines granulates
AT412344B (de) * 2001-04-12 2005-01-25 Sandoz Ag Hydrophobisierte teilchen von k-clavulanat
AU2003238670A1 (en) * 2002-04-05 2003-10-27 Cadila Healthcare Limited Fast disintegrating oral dosage forms
EP1539146A1 (de) * 2002-07-16 2005-06-15 Ranbaxy Laboratories, Ltd. Dispergierbare tabletten zur oralen verabreichung
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005009368A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
EP1653925A1 (de) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
EP1653924A4 (de) * 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
EP1720533B1 (de) * 2004-02-24 2015-03-25 Sandoz Ag Amoxicillin-instantgranulat
JP2006527064A (ja) * 2004-05-31 2006-11-30 サンア ファーマシューティカルス カンパニー リミテッド β−ラクタム系抗生物質を含む懸濁錠剤及びその製造方法
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2006222061B2 (en) 2005-03-03 2011-04-28 Janssen Pharmaceutica N.V. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
WO2007058397A1 (en) * 2005-11-17 2007-05-24 Gl Pharmtech Corp. A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
AP2986A (en) 2007-02-23 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
WO2009055038A1 (en) 2007-10-26 2009-04-30 Rexahn Pharmaceuticals, Inc. Pharmaceutical formulation of clavulanic acid
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
WO2009135179A2 (en) 2008-05-02 2009-11-05 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2009135946A1 (en) 2008-05-09 2009-11-12 Atacama Labs Oy Method and apparatus for dry granulation
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074689A1 (es) * 2008-12-19 2011-02-02 Solvay Pharm Bv Formulaciones farmaceuticas de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral. proceso de preparacion
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2493312B1 (de) 2009-10-26 2021-10-20 Merck Sharp & Dohme Corp. Feste pharmazeutische zusammensetzungen mit einem integrasehemmer
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2519229A2 (de) 2009-12-29 2012-11-07 Novartis AG Neue pharmazeutische darreichungsform zur behandlung von magensäurebedingten erkrankungen
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
AR082091A1 (es) * 2010-05-05 2012-11-14 Boehringer Ingelheim Int Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
EP2566469B1 (de) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Kombinationstherapie
EP2585101A1 (de) 2010-06-24 2013-05-01 Boehringer Ingelheim International GmbH Diabetestherapie
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2882423A1 (de) * 2012-08-07 2015-06-17 Sandoz AG Unbeschichtete tablette mit granulat mit einem beta-lactam-antibiotikum und stark dispergiertem silikondioxid
JP2014079286A (ja) * 2012-10-12 2014-05-08 Hiroaki Koga 抗菌剤入容器
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
PL3518924T3 (pl) 2016-09-30 2023-01-09 Salix Pharmaceuticals, Inc. Postacie stałej dyspersji ryfaksyminy
BR112019007564A2 (pt) * 2016-10-24 2019-07-02 Janssen Sciences Ireland Unlimited Company composições dispersíveis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552416A (en) * 1975-08-12 1979-09-12 Beecham Group Ltd Pharmaceutical compositions
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics

Also Published As

Publication number Publication date
HUT67020A (en) 1995-01-30
CN1067577A (zh) 1993-01-06
US20020064562A1 (en) 2002-05-30
US6544558B2 (en) 2003-04-08
EP0783889A1 (de) 1997-07-16
WO1992019227A3 (en) 1992-12-23
ATE203400T1 (de) 2001-08-15
YU47892A (sh) 1994-12-28
DE69231965T2 (de) 2002-04-04
GR3036937T3 (en) 2002-01-31
NO934009L (no) 1993-11-05
ATE252900T1 (de) 2003-11-15
NO312224B1 (no) 2002-04-15
MX9202118A (es) 1993-03-01
CN1265882A (zh) 2000-09-13
GB9109862D0 (en) 1991-07-03
AU1649892A (en) 1992-12-21
CA2102630C (en) 2004-01-13
SK282333B6 (sk) 2002-01-07
BR9205948A (pt) 1994-11-08
TW240172B (de) 1995-02-11
DE69233239D1 (de) 2003-12-04
EP0585252A1 (de) 1994-03-09
YU49069B (sh) 2003-08-29
AP328A (en) 1994-03-23
EP0585252B1 (de) 2001-07-25
US6352720B1 (en) 2002-03-05
SG55163A1 (en) 1998-12-21
DE69233239T2 (de) 2004-08-19
DE69233464T2 (de) 2006-04-13
WO1992019227A2 (en) 1992-11-12
CN1056277C (zh) 2000-09-13
EP0787487B1 (de) 2004-12-22
DK0585252T3 (da) 2001-11-12
IL101795A0 (en) 1992-12-30
DE69233464D1 (de) 2005-01-27
CA2102630A1 (en) 1992-11-09
KR100228450B1 (ko) 1999-11-01
ES2235210T3 (es) 2005-07-01
NZ242625A (en) 1994-08-26
ES2212034T3 (es) 2004-07-16
FI934914A0 (fi) 1993-11-05
US6110497A (en) 2000-08-29
EP0783889B1 (de) 2003-10-29
MA22522A1 (fr) 1992-12-31
MY111879A (en) 2001-02-28
ZA923272B (en) 1993-03-31
DE69231965D1 (de) 2001-08-30
IE921472A1 (en) 1992-11-18
FI110354B (fi) 2002-12-31
CZ237993A3 (en) 1994-03-16
NO934009D0 (no) 1993-11-05
CN1155370C (zh) 2004-06-30
HU9303143D0 (en) 1994-01-28
FI934914A (fi) 1993-11-05
EP0787487A1 (de) 1997-08-06
ES2161690T3 (es) 2001-12-16
PT100458B (pt) 1999-07-30
IL101795A (en) 1996-10-16
HU219348B (en) 2001-03-28
AP9200382A0 (en) 1992-07-31
SA92130069B1 (ar) 2005-04-16
PT100458A (pt) 1993-08-31
AU659836B2 (en) 1995-06-01
CZ291795B6 (cs) 2003-05-14
SK112793A3 (en) 1994-06-08
JPH06507396A (ja) 1994-08-25

Similar Documents

Publication Publication Date Title
ATE285227T1 (de) Pharmazeutische granulate mit intragranulärem sprengmittel
ATA129892A (de) Pharmazeutische zusammensetzung
NO20001227D0 (no) Medikamenter
FI921060A (fi) Farmaceutiska aerosolformuleringar
FI922252A (fi) Farmaceutisk sammansaettning
FI922316A (fi) Farmaceutisk sammansaettning
FI923581A (fi) Farmaceutisk kombinationsformation
DE10199066I1 (de) Pharmazeutische Zusammensetzung
NO923859D0 (no) Medikament
DE4291156T1 (de) Verbesserte pharmazeutische Zusammensetzungen
DE68918847D1 (de) Stabile pharmazeutische zusammensetzung.
BR8907675A (pt) Gatilho de engate rapido
DE4294862T1 (de) Pharmazeutische Komposition
FI905236A0 (fi) Deoxiribonukleosider innehaollande farmaceutiska konsistenser foer laekning av saor.
FI955605A0 (fi) Aryloivia lääkkeitä
ATE269695T1 (de) Pharmazeutische pellets
NO961589D0 (no) Farmasöytiske blandinger
DE68915203D1 (de) Pharmazeutische Mischungen.
DK5593D0 (da) Granulat
DE69416246D1 (de) Granulator
FI921786A (fi) Farmaceutisk foerening
FI921785A (fi) Farmaceutisk foerening
DE69223905D1 (de) Avermectin-Verbindungen mit einem 6,5-Spiroketal-Ringsystem und einem 23-Acyl-Substituenten
DK159643C (da) Granuleringsproces
DE69218461D1 (de) Pharmazeutische mischung mit antineoplastischer wirksamkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties